Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
formoterol + Aerochamber Plus
- Development stage
- Unknown
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Formoterol + Aerochamber Plus refers to the long-acting beta-2 adrenergic receptor agonist (LABA) formoterol fumarate administered via a pressurized metered-dose inhaler (pMDI) in conjunction with the Aerochamber Plus spacer device. Formoterol acts as a potent bronchodilator by selectively stimulating beta-2 receptors in the lungs, leading to the relaxation of bronchial smooth muscle and improved airflow. The use of the Aerochamber Plus spacer is intended to optimize drug delivery to the lower airways and reduce oropharyngeal deposition, which is particularly beneficial for pediatric patients and those with poor inhaler technique. This specific drug-device combination has been evaluated by Chiesi Farmaceutici in clinical pharmacology studies, often as a comparator to fixed-dose combinations like beclometasone/formoterol (CHF 1535), to characterize the pharmacokinetic profile and systemic availability of formoterol in asthmatic populations.
- Brand names
- AtimosForadil
- Other names
- formoterol fumarateformoterol + AC Plus
02
Targets
ADRB3 (β3)ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on formoterol + Aerochamber Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on formoterol + Aerochamber Plus.